Literature DB >> 7975828

Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.

C J Lee1, R A Lock, P W Andrew, T J Mitchell, D Hansman, J C Paton.   

Abstract

The immunogenicity and protective efficacy of a conjugate of Streptococcus pneumoniae type 19F polysaccharide and a genetically toxoided derivative of the pneumococcal toxin pneumolysin was investigated in an infant mouse model. The conjugate was administered to Balb/c mice during pregnancy and/or lactation, and to their offspring during early infancy. The anti-polysaccharide and anti-pneumolysin titres of the immunized infant mice were significantly higher than those of non-immunized controls. When the infant mice were challenged with type 19F pneumococci, the bacteria were cleared more effectively from the blood of immunized mice than from that of control mice. The survival rate for the immunized mice was also significantly higher than that for the control group. These results indicate that highly protective anti-pneumococcal responses can be induced in infant mice by immunization with the conjugate during gestation or early infancy, and suggest a possible role for pneumolysoid-polysaccharide conjugates as human vaccine components.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975828     DOI: 10.1016/0264-410x(94)90028-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.

Authors:  J Kuo; M Douglas; H K Ree; A A Lindberg
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

3.  Pneumococcal Vaccination in Adults.

Authors:  Tsering Y Sherpa; Howard L Leaf
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

4.  Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.

Authors:  Jun-Young Seo; Seung Yong Seong; Byung-Yoon Ahn; Ick Chan Kwon; Hesson Chung; Seo Young Jeong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae.

Authors:  A M Berry; J C Paton
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.

Authors:  A D Ogunniyi; R L Folland; D E Briles; S K Hollingshead; J C Paton
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Roles of autolysin and pneumolysin in middle ear inflammation caused by a type 3 Streptococcus pneumoniae strain in the chinchilla otitis media model.

Authors:  K Sato; M K Quartey; C L Liebeler; C T Le; G S Giebink
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

8.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model.

Authors:  S J Devi; U Hayat; C E Frasch; A S Kreger; J G Morris
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

Review 10.  New vaccines for the prevention of pneumococcal infections.

Authors:  H Käyhty; J Eskola
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.